Lux Biosciences to Present at the Thomas Weisel Partners Health Care Conference

JERSEY CITY, NJ (September 8, 2009): Lux Biosciences, a privately held biotechnology company focused on the treatment of ophthalmic diseases, announced today that Ulrich Grau, Ph.D., the company’s president and chief executive officer, will present at the Thomas Weisel Partner’s Health Care Conference on Thursday September 10 at 2:05 pm Eastern. The conference is being held in Boston from September 9-11 at the Four Seasons Hotel. Dr. Grau will provide an overview of Lux Biosciences’ development programs and corporate objectives.

About Lux Biosciences

Lux Biosciences, Inc. is a privately held biotechnology company focused on the treatment of ophthalmic diseases. The company has a staged product portfolio that includes potential first-in-class therapies with a short-term path to commercialization and high revenue potential. The portfolio includes:

• A submission-stage project, LUVENIQ™, the oral formulation of a next-generation calcineurin inhibitor (voclosporin) for which positive phase 3 data have recently been obtained for the treatment of sight-threatening non-infectious uveitis. The 0.4 mg/kg BID dose was superior to placebo in reducing active posterior segment inflammation at both Week 16 (p<0.01) and Week 24 (p<0.05). In a second study, LUVENIQ at the 0.4 mg/kg BID dose demonstrated a 50% greater reduction in inflammatory exacerbation rate at 6 months than placebo (p<0.05) in subjects with medically controlled posterior segment disease. Lux Biosciences is collaborating with the team at Isotechnika Pharma who invented the molecule and develop it for other indications.

• A Phase 3 clinical-stage project, LUMITECT™, a silicone matrix ocular (episcleral) implant that continuously elutes cyclosporine A locally to the eye for the prevention of rejection in high risk corneal transplantation. The LUCIDA pivotal clinical program with LUMITECT™, for the prevention of corneal transplant rejection completed patient recruitment in March 2009 and first results are expected in late 2009.

• LX214, a novel topical eye drop formulation for dry eye syndrome that completed Phase 1 clinical testing in June 2009. Utilizing voclosporin and Lux’s proprietary topical formulation technology, LX214 establishes high levels of drug concentration in relevant ocular tissues and was well tolerated in both animals and human volunteers. In addition to dry eye, LX214 has potential value in other chronic inflammatory diseases of the eye, such as blepharitis and atopic keratoconjunctivitis.

• Several earlier stage projects based on proprietary product-enabling bio-erodible polymer technologies that facilitate targeted and sustained delivery of molecules to the eye.

For more information on Lux Biosciences, please visit the company’s website at http://www.luxbio.com.

###

CONTACTS:
Lux Biosciences, Inc.
Ulrich Grau, Ph.D.
+1 201-946-0221
Ulrich.grau@luxbio.com

Kureczka/Martin Associates (media)
Joan Kureczka
+1 415-821-2413
Mobile +1 415-690-0210
Jkureczka@comcast.net